Actual status of veralipride use

Sebastián Carranza-LiraReproductive Medicine Service. Hospital de Ginecología y Obstetricia “Luis Castelazo Ayala” Instituto Mexicano del Seguro Social, México DFAbstract: During the climacteric period, several symptoms exist that motivate women t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Sebastián Carranza-Lira
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	veralipride hot-flushes climacteric menopause symptoms secondary effects Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/7e140715dd9c437399085e0a68cb9249
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7e140715dd9c437399085e0a68cb9249
record_format	dspace
spelling	oai:doaj.org-article:7e140715dd9c437399085e0a68cb92492021-12-02T02:37:13ZActual status of veralipride use1178-1998https://doaj.org/article/7e140715dd9c437399085e0a68cb92492010-09-01T00:00:00Zhttps://www.dovepress.com/actual-status-of-veralipride-use-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Sebastián Carranza-LiraReproductive Medicine Service. Hospital de Ginecología y Obstetricia “Luis Castelazo Ayala” Instituto Mexicano del Seguro Social, México DFAbstract: During the climacteric period, several symptoms exist that motivate women to seek medical advice; one of the most common is the hot flush, which presents in 75%–85% of these during a variable time span. For the treatment of hot flush, several non-hormonal treatments exist; among them, veralipride has shown to be a useful treatment of vasomotor symptoms during the climacteric period. In recent times, several medical societies have discredited its use. The purpose of this review, therefore, is to define a measured position in relation to the use of this drug. On completion of this review, it was possible to conclude that this drug has an antidopaminergic mechanism of action. The recommended schedule is: 100 mg/day for 20 days, with 10 days drug free. Since the risk of undesirable secondary effects such as galactorrhea, mastodynia, and extrapyramidal can increase with use, no more than 3 treatment cycles are recommended. This drug has a residual effect that can allow drug-free intervals, which permit a longer time between schedules.Keywords: veralipride, hot flushes, climacteric, menopause, symptoms, secondary effectsSebastián Carranza-LiraDove Medical Pressarticleveralipridehot-flushesclimactericmenopausesymptomssecondary effectsGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 5, Pp 271-276 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	veralipride hot-flushes climacteric menopause symptoms secondary effects Geriatrics RC952-954.6
spellingShingle	veralipride hot-flushes climacteric menopause symptoms secondary effects Geriatrics RC952-954.6 Sebastián Carranza-Lira Actual status of veralipride use
description	Sebastián Carranza-LiraReproductive Medicine Service. Hospital de Ginecología y Obstetricia “Luis Castelazo Ayala” Instituto Mexicano del Seguro Social, México DFAbstract: During the climacteric period, several symptoms exist that motivate women to seek medical advice; one of the most common is the hot flush, which presents in 75%–85% of these during a variable time span. For the treatment of hot flush, several non-hormonal treatments exist; among them, veralipride has shown to be a useful treatment of vasomotor symptoms during the climacteric period. In recent times, several medical societies have discredited its use. The purpose of this review, therefore, is to define a measured position in relation to the use of this drug. On completion of this review, it was possible to conclude that this drug has an antidopaminergic mechanism of action. The recommended schedule is: 100 mg/day for 20 days, with 10 days drug free. Since the risk of undesirable secondary effects such as galactorrhea, mastodynia, and extrapyramidal can increase with use, no more than 3 treatment cycles are recommended. This drug has a residual effect that can allow drug-free intervals, which permit a longer time between schedules.Keywords: veralipride, hot flushes, climacteric, menopause, symptoms, secondary effects
format	article
author	Sebastián Carranza-Lira
author_facet	Sebastián Carranza-Lira
author_sort	Sebastián Carranza-Lira
title	Actual status of veralipride use
title_short	Actual status of veralipride use
title_full	Actual status of veralipride use
title_fullStr	Actual status of veralipride use
title_full_unstemmed	Actual status of veralipride use
title_sort	actual status of veralipride use
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/7e140715dd9c437399085e0a68cb9249
work_keys_str_mv	AT sebastiaacutencarranzalira actualstatusofveraliprideuse
_version_	1718402297992577024

Actual status of veralipride use

Ejemplares similares